EE200100651A - VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks - Google Patents
VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviksInfo
- Publication number
- EE200100651A EE200100651A EEP200100651A EEP200100651A EE200100651A EE 200100651 A EE200100651 A EE 200100651A EE P200100651 A EEP200100651 A EE P200100651A EE P200100651 A EEP200100651 A EE P200100651A EE 200100651 A EE200100651 A EE 200100651A
- Authority
- EE
- Estonia
- Prior art keywords
- vla
- inflammation
- treatment
- monoclonal antibody
- blocking monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13703899P | 1999-06-01 | 1999-06-01 | |
US18533600P | 2000-02-29 | 2000-02-29 | |
PCT/US2000/015004 WO2000072881A1 (en) | 1999-06-01 | 2000-06-01 | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200100651A true EE200100651A (et) | 2003-02-17 |
Family
ID=26834850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200100651A EE200100651A (et) | 1999-06-01 | 2000-06-01 | VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks |
Country Status (28)
Country | Link |
---|---|
US (5) | US6955810B2 (zh) |
EP (3) | EP1488806B1 (zh) |
JP (6) | JP4817503B2 (zh) |
CN (1) | CN1309419C (zh) |
AU (2) | AU783989B2 (zh) |
BG (1) | BG65579B1 (zh) |
BR (1) | BR0011250A (zh) |
CA (1) | CA2375827C (zh) |
CY (1) | CY1116042T1 (zh) |
CZ (1) | CZ300710B6 (zh) |
DK (2) | DK2314315T3 (zh) |
EA (1) | EA011384B1 (zh) |
EE (1) | EE200100651A (zh) |
ES (2) | ES2529706T3 (zh) |
GE (1) | GEP20063774B (zh) |
HK (2) | HK1043320A1 (zh) |
HU (1) | HUP0202568A3 (zh) |
IL (2) | IL146508A0 (zh) |
IS (1) | IS6179A (zh) |
MX (1) | MXPA01012388A (zh) |
NO (1) | NO20015864L (zh) |
NZ (1) | NZ515686A (zh) |
PT (2) | PT2314315E (zh) |
SI (2) | SI1488806T1 (zh) |
SK (1) | SK17232001A3 (zh) |
TR (1) | TR200103432T2 (zh) |
WO (1) | WO2000072881A1 (zh) |
YU (1) | YU85501A (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2375827C (en) | 1999-06-01 | 2017-01-10 | Biogen, Inc. | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
AR036330A1 (es) | 2001-04-13 | 2004-09-01 | Biogen Inc | Un anticuerpo anti-vla-1, una composicion que lo incluye, un acido nucleico aislado consistente en una secuencia de codificacion de dicho anticuerpo, un metodo para determinar el nivel de vla-1 en un tejido, celulas del hibridoma de dicho anticuerpo, una computadora que produce una representacion tr |
AU2003215298A1 (en) * | 2002-02-14 | 2003-09-04 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
EP1562632B1 (en) * | 2002-11-01 | 2012-12-05 | Boys Town National Research Hospital | Inducible ligand for alpha1 beta1 integrin and uses |
WO2005004800A2 (en) * | 2003-06-20 | 2005-01-20 | Morehouse School Of Medicine | Trypanosome derived apoptotic factors (taf) |
WO2005057755A1 (en) * | 2003-12-09 | 2005-06-23 | Electrotechnologies Selem, Inc. | Polyphase claw-pole machines with a segmented magnetic circuit |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
WO2006133286A2 (en) * | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
EP2839843B1 (en) * | 2006-05-25 | 2018-06-20 | Biogen MA Inc. | VLA-1 antagonist for use in treating stroke |
EP2279209A2 (en) * | 2008-05-09 | 2011-02-02 | Ablynx NV | Amino acid sequences directed against integrins and uses thereof |
JP6324720B2 (ja) * | 2010-06-18 | 2018-05-16 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 関節炎治療 |
US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
MA49645A (fr) | 2017-07-20 | 2021-03-31 | Univ Virginia Patent Foundation | Procédés de traitement ou de prévention d'un trouble neurologique du système immunitaire |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5391481A (en) * | 1990-08-31 | 1995-02-21 | The Trustees Of Columbia University | Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
DE69309044T3 (de) | 1992-01-13 | 2004-12-23 | Biogen, Inc., Cambridge | Behandlung von asthma |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
ES2137354T3 (es) | 1993-01-12 | 1999-12-16 | Biogen Inc | Moleculas de anticuerpo anti-vla4 recombinante. |
WO1994017828A2 (en) | 1993-02-09 | 1994-08-18 | Biogen, Inc. | Treatment for insulin dependent diabetes |
US6111598A (en) | 1993-11-12 | 2000-08-29 | Peveo, Inc. | System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
WO1995019790A1 (en) | 1994-01-25 | 1995-07-27 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
DK0759302T3 (da) | 1994-04-26 | 2000-11-13 | Kanebo Ltd | Middel mod rheumatoid arthritis |
JPH08131185A (ja) * | 1994-11-14 | 1996-05-28 | Sumitomo Electric Ind Ltd | マウスvla−1分子に対するモノクローナル抗体 |
JPH08160972A (ja) | 1994-12-01 | 1996-06-21 | Sega Enterp Ltd | エフェクト制御方法、制御装置およびこれを利用したカラオケ装置 |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9516399D0 (en) | 1995-08-10 | 1995-10-11 | Camelot Superabsorbents Ltd | Process for the production of water-absorbing compositions |
PT859841E (pt) | 1995-08-18 | 2002-11-29 | Morphosys Ag | Bibliotecas de proteinas/ (poli) peptidos |
EP1916300A1 (en) | 1995-08-29 | 2008-04-30 | Kirin Pharma Kabushiki Kaisha | Chimeric animal and method for producing the same |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
GB9519667D0 (en) | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
FR2745912B1 (fr) * | 1996-03-08 | 1998-05-29 | Lorraine Laminage | Procede et dispositif de controle de la soudabilite de toles sandwich |
US6127524A (en) | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
CA2292730C (en) | 1997-06-13 | 2008-09-16 | Genentech, Inc. | Stabilized antibody formulation |
BR9911067A (pt) | 1998-05-22 | 2001-02-06 | Boys Town Nat Res Hospital | Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal |
DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
EP1119583A1 (en) | 1998-10-06 | 2001-08-01 | Biogen, Inc. | Crystals of the alpha 1 beta 1 integrin i-domain and their use |
DE60020955T2 (de) * | 1999-04-22 | 2006-05-11 | Biogen Idec Ma Inc., Cambridge | Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha-4 untereinheit |
CA2375827C (en) * | 1999-06-01 | 2017-01-10 | Biogen, Inc. | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
US7601125B1 (en) | 1999-06-17 | 2009-10-13 | Desinger Kai | Surgical, grooved director for collecting tissue in a minimally invasive manner |
AU4259901A (en) | 2000-03-28 | 2001-10-08 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
DE10028402A1 (de) | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
US7153944B2 (en) | 2000-07-31 | 2006-12-26 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
AR036330A1 (es) | 2001-04-13 | 2004-09-01 | Biogen Inc | Un anticuerpo anti-vla-1, una composicion que lo incluye, un acido nucleico aislado consistente en una secuencia de codificacion de dicho anticuerpo, un metodo para determinar el nivel de vla-1 en un tejido, celulas del hibridoma de dicho anticuerpo, una computadora que produce una representacion tr |
AU2003215298A1 (en) | 2002-02-14 | 2003-09-04 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
CA2494310A1 (en) | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
US20040208870A1 (en) | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
WO2005019177A1 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof |
US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
WO2006133286A2 (en) | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
EP2839843B1 (en) | 2006-05-25 | 2018-06-20 | Biogen MA Inc. | VLA-1 antagonist for use in treating stroke |
JP4951596B2 (ja) | 2008-07-31 | 2012-06-13 | 株式会社日立製作所 | 冷却システム及び電子装置 |
TW201039854A (en) | 2009-03-06 | 2010-11-16 | Genentech Inc | Antibody formulation |
CN107095846A (zh) | 2009-12-21 | 2017-08-29 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
WO2012106497A2 (en) | 2011-02-03 | 2012-08-09 | Santarus, Inc. | Selection and treatment of subjects |
US9018035B2 (en) | 2012-01-11 | 2015-04-28 | Panasonic Intellectual Property Management Co., Ltd. | Pressed-contact type semiconductor device and method for manufacturing the same |
US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
-
2000
- 2000-06-01 CA CA2375827A patent/CA2375827C/en not_active Expired - Lifetime
- 2000-06-01 YU YU85501A patent/YU85501A/sh unknown
- 2000-06-01 SI SI200031089T patent/SI1488806T1/sl unknown
- 2000-06-01 SK SK1723-2001A patent/SK17232001A3/sk unknown
- 2000-06-01 DK DK10185467.7T patent/DK2314315T3/en active
- 2000-06-01 EA EA200400930A patent/EA011384B1/ru not_active IP Right Cessation
- 2000-06-01 PT PT10185467T patent/PT2314315E/pt unknown
- 2000-06-01 PT PT40181513T patent/PT1488806E/pt unknown
- 2000-06-01 SI SI200031087T patent/SI2314315T1/sl unknown
- 2000-06-01 ES ES10185467.7T patent/ES2529706T3/es not_active Expired - Lifetime
- 2000-06-01 DK DK04018151.3T patent/DK1488806T3/en active
- 2000-06-01 GE GE5125A patent/GEP20063774B/en unknown
- 2000-06-01 TR TR2001/03432T patent/TR200103432T2/xx unknown
- 2000-06-01 HU HU0202568A patent/HUP0202568A3/hu unknown
- 2000-06-01 JP JP2000620987A patent/JP4817503B2/ja not_active Expired - Lifetime
- 2000-06-01 NZ NZ515686A patent/NZ515686A/en unknown
- 2000-06-01 IL IL14650800A patent/IL146508A0/xx active IP Right Grant
- 2000-06-01 CZ CZ20014249A patent/CZ300710B6/cs not_active IP Right Cessation
- 2000-06-01 MX MXPA01012388A patent/MXPA01012388A/es active IP Right Grant
- 2000-06-01 EP EP04018151.3A patent/EP1488806B1/en not_active Expired - Lifetime
- 2000-06-01 EE EEP200100651A patent/EE200100651A/xx unknown
- 2000-06-01 CN CNB008084289A patent/CN1309419C/zh not_active Expired - Lifetime
- 2000-06-01 EP EP10185467.7A patent/EP2314315B1/en not_active Expired - Lifetime
- 2000-06-01 ES ES04018151.3T patent/ES2557768T3/es not_active Expired - Lifetime
- 2000-06-01 EP EP00942654A patent/EP1181054A1/en not_active Withdrawn
- 2000-06-01 AU AU57248/00A patent/AU783989B2/en not_active Expired
- 2000-06-01 WO PCT/US2000/015004 patent/WO2000072881A1/en active Application Filing
- 2000-06-01 BR BR0011250-0A patent/BR0011250A/pt not_active Application Discontinuation
-
2001
- 2001-11-15 IL IL146508A patent/IL146508A/en not_active IP Right Cessation
- 2001-11-28 IS IS6179A patent/IS6179A/is unknown
- 2001-11-30 NO NO20015864A patent/NO20015864L/no not_active Application Discontinuation
- 2001-11-30 US US09/996,738 patent/US6955810B2/en not_active Expired - Lifetime
- 2001-12-17 BG BG106226A patent/BG65579B1/bg unknown
-
2002
- 2002-07-12 HK HK02105185.2A patent/HK1043320A1/zh unknown
-
2005
- 2005-04-18 US US11/108,581 patent/US7462353B2/en not_active Expired - Lifetime
-
2006
- 2006-04-12 AU AU2006201540A patent/AU2006201540A1/en not_active Abandoned
-
2007
- 2007-05-22 JP JP2007136041A patent/JP2007277253A/ja active Pending
-
2008
- 2008-11-11 US US12/268,459 patent/US8084031B2/en not_active Expired - Fee Related
-
2011
- 2011-05-24 JP JP2011116366A patent/JP5623335B2/ja not_active Expired - Lifetime
- 2011-08-15 HK HK11108559.3A patent/HK1154352A1/zh not_active IP Right Cessation
- 2011-11-15 US US13/296,778 patent/US8557240B2/en not_active Expired - Fee Related
-
2012
- 2012-06-07 JP JP2012130177A patent/JP2012176983A/ja active Pending
-
2013
- 2013-09-09 US US14/021,547 patent/US9902774B2/en not_active Expired - Fee Related
-
2014
- 2014-08-18 JP JP2014165702A patent/JP5960762B2/ja not_active Expired - Lifetime
-
2015
- 2015-02-20 CY CY20151100186T patent/CY1116042T1/el unknown
-
2016
- 2016-03-24 JP JP2016060029A patent/JP2016121184A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300528A (et) | Cripto valku blokeerivad antikehad ja nende kasutamine | |
EE200100651A (et) | VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks | |
DE60039589D1 (de) | Rekombinante il-18 antikörper und deren verwendung | |
DE60229509D1 (de) | Anti-osteopontin-antikörper und dessen verwendung | |
CY2013010I1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 | |
ZA963287B (en) | Modified anti-icam-1 antibodies and their use in the treatment of inflammation | |
ID28576A (id) | Aparatus pelindung untuk penggunaan dalam hubungannya dengan perkakas sumuran dan metode untuk perlindungan kumparan | |
DE60034476D1 (de) | Topische nasenbehandlung mit desloratadin und mometason furoat | |
NO20022174D0 (no) | Anvendelse av anti-CD40L-antistoff i kombinasjon med anti- CD20-antistoff og/eller kjemoterapeutika og radioterapi vedbehandling av B-cellesykdommer | |
DE50009607D1 (de) | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung | |
NO20016035D0 (no) | Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter | |
ATE384695T1 (de) | Carbamat caspase inhibitoren und deren verwendung | |
EE05507B1 (et) | Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks | |
LV12624B (lv) | Tienilazolilalkosietanamini to iegusanas panemiens un pielietojums medikamentu legusana | |
DK1411064T3 (da) | Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer | |
AU7676300A (en) | Human anti-adipocyte monoclonal antibodies and their use | |
HUP0101151A3 (en) | Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin | |
DE69817579D1 (de) | Monoklonaler Antikörper gegen das humanen CD21 und dessen Verwendungen | |
AU2003211292A1 (en) | Monoclonal antibody against human hepatoma and use thereof | |
ATA3042000A (de) | Schallabsorptionselement und dessen verwendung | |
NO20014454D0 (no) | Konstruksjon og anvendelse av samme | |
DE69126302D1 (de) | Monoklonaler antikörper gegen herzglykosid und dessen verwendung | |
IT241433Y1 (it) | Bendaggio per il trattamento conservativo delle fratture di clavicola, a doppio tiraggio e fissaggio posteriore sia orizzontale che | |
GB9907151D0 (en) | Therapeutic antibody composition and use | |
GB9901689D0 (en) | Therapeutic antibody composition and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change of owner name |